Median Technologies to present at Cowen and Company 37th Annual Health Care Conference

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis™ we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

Learn More

Request a Demo

Press release – For immediate release – February 28, 2017 – 17:45 CET – Sophia Antipolis, France

MEDIAN Technologies (ALMDT.PA), the Imaging Phenomics™ Company, announced today that Fredrik Brag, Median’s Chief Executive Officer, will provide an overview of the Company and its strategic objectives at the Cowen and Company 37^th Annual Health Care Conference. The presentation will take place on Tuesday, March 7^th at 08:40 am EST at the Marriott Copley Place in Boston, Massachusetts, USA.

Back to press releases